Further analysis on this synergism leads to the discovery of the immuno-stimulatory effect of several FLT3 tyrosine kinase inhibitors (FLT3-TKIs), such as sorafenib, tandutinib, midostaurin, crenolanib, quizartinib, through induction of IL15-production in the AML cells (Fig. 1) [20]. This evidence concerns the gene IL15 and acute myeloid leukemia.